Table 2 Baseline comparison between treatment and placebo groups
Variable | HDM impermeable bedding, n = 26 | Placebo bedding, n = 21 |
|---|---|---|
Age, mean (sd) | 10.58 (2.34) | 11.57 (2.08) |
Males (%) | 16 (62) | 13 (62) |
Peak expiratory flow in litres/min, mean (sd) | 288.80 (100.80) | 328.57 (73.02) |
Number on inhaled steroids (%) | 5 (19.2) | 5 (23.8) |
28-day asthma symptom score (0–336), median (inter-qaurtile range) | 12.0 (6.5 to 52.5) | 37.0 (9.0 to 69.0) |
28-day rhinitis symptom score (0–252), median (inter-quartile range) | 50.5 (19.8 to 82.5) | 51.0 (23.5 to 84.5) |
Episodes of night-time waking over 28 days, median (inter-quartile range) | 0 (0 to 0.75) | 0 (0 to 3.0) |
28-day dose inhaled steroid mcg/month, median (inter-quartile range) | 5600 (1450 to 11,100) | 5400 (58 to 11,200) |
28-day dose bronchodilator mcg/month, median (inter-quartile range) | 800 (125 to 1700) | 400 (100 to 42) |